An observational study in Documenta Ophthalmologica found the MLSDT showed reliability above 0.50 in advanced retinitis pigmentosa and correlated with visual acuity, visual fields and patient-reported outcomes. The test is being used as a secondary endpoint in the phase 2b/3 RESTORE trial of MCO-010.
Ocugen will host a conference call on March 4, 2026 at 8:30 a.m. ET to discuss fourth quarter and full year 2025 financial results and provide a business update, with a pre-market earnings announcement the same day.
AAV-based gene therapy offers sustained intraocular delivery of anti-angiogenic agents with a single treatment for neovascular AMD, with leading clinical candidates including RGX-314, ADVM-022, 4D-150, and NG101.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06839170 |
An Assistant Model for IRD Care Needs: A Randomized Control Trial |
COMPLETED | NA |
| NCT06749639 |
Safety and Efficacy Study of PUMCH-E101 Injection in Subjects with RDH12 Retinopathy |
RECRUITING | EARLY_PHASE1 |
| NCT06699108 |
Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06651736 |
Optimizing Low Vision Rehabilitation in Emotionally Distressed Patients With Inherited Retinal Diseases |
RECRUITING | NA |
| NCT05957276 |
Global Patient Registry of Inherited Retinal Diseases |
ACTIVE_NOT_RECRUITING |
